Neurology, Neuropsychiatry, Psychosomatics

Advanced search

New possibilities of neuroprotection in ischemic stroke

Full Text:


Reperfusion and neuroprotection are two present-day therapy strategies for patients with acute stroke. The paper reviews currently available drugs used for neuroprotection in ischemic strokes in the context of evidence-based medicine.


1. <div><p>Feigin V.L., Lawes C.M.M., Bennett D.A. et al. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol 2009;8(4):355-69.</p><p>Исмагилов М.Ф., Василевская О.В., Гайфутдинов Р.Т. и др. Оценка эффективности церетона в остром периоде ишемического инсульта. Журн неврол и психиатр 2009;3:35-6.</p><p>Adams H.P., Jr, del Zoppo G., Alberts M.J. et al. Guidelines for the Early Management of Adults With Ischemic Stroke. Stroke 2007;38:1655-711.</p><p>Hacke W. Kaste M., Bluhmki E. et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359(13):1317-29.</p><p>Warlow C., van Gijn J., Dennis M. et al. Stroke: practical management. 3rd ed. Oxford: Blackwell Publishung, 2008;551 р.</p><p>The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.</p><p>Ginsberg M.D. Current Status of Neuroprotection for Cerebral Ischemia. Synoptic Overview. Stroke 2009;40:S111-S114.</p><p>Feuerstein G.Z., Chavez J. Translational Medicine for Stroke Drug Discovery: The Pharmaceutical Industry Perspective. Stroke 2009;40:S121-S125.</p><p>O'Collins V.E., Macleod M.R., Donnan G.A. et al. 1026 experimental treatments in acute stroke. Ann Neurol 2006;59:467-77</p><p>Martinez-Vila E., Sieira P. Current status and perspectives of neuroprotection in ischemic stroke treatment. Cerebrovasc Dis 2001;11(Suppl. 1):60-70.</p><p>Philip M., Benatar M., Fisher M. et al. Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials. Stroke 2009;40(2):577-81.</p><p>Lees K.R., Zivin J.A., Ashwood T. et al. NXY-059 for acute ischemic stroke. N Engl J Med 2006;354:588-600.</p><p>Shuaib A., Lees K.R., Lyden P. et al. NXY059 for the treatment of acute ischemic stroke. N Engl J Med 2007;357:562-71.</p><p>Savitz S.I., Fisher M. Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials. Ann Neurol 2007;61(5):396-402.</p><p>Green A.R., Odergren T, Ashwood T. Animal models of stroke: do they have value for discovering neuroprotective agents. Trends Pharmacol Sci 2003;24:402-8.</p><p>Stroke Therapy Academic Industry Roundtable. Recommendations for standards regarding pre-clinical neuroprotective and restorative drug development. Stroke 1999;30:2752-8.</p><p>Stroke Therapy Academic Industry Roundtable II. Stroke Therapy Academic Industry Roundtable II (STAIR-II). Stroke 2001;32:1598-606.</p><p>Bernard S.A., Gray T.W., Buist M.D. et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med 2002;346:557-63.</p><p>Ovbiagele B., Kidwell C.S., Starkman al. Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep 2003;3:9-20.</p><p>Muir K.W., Ford I., Reid J.L. et al. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. Lancet 2004;363:439-45.</p><p>Saver J.L., Eckstein M., Stratton S.J. et al. for the FAST-MAG Investigators. The Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Phase 3 Clinical Trial. Ongoing Clinical Trial Poster Session Abstract Book, 29th International Stroke Conference, San Diego, CA, February 5, 2004.</p><p>Muller W.E., Mь ller W.E., Eckert G.P. et al. Piracetam: novelty in a unique mode of action. Pharmacopsychiatry 1999;32:2-9.</p><p>Winblad B. Piracetam: a review of pharmacological properties and clinical uses. CNS. Drug Rev 2005;11:169-82.</p><p>De Deyn P.P., Reuck J.D., Deberdt W. et al. Treatment of acute ischemic stroke with piracetam. Members of the Piracetam in Acute Stroke Study (PASS) Group. Stroke 1997;28:2347-52.</p><p>Луцкий М.А. Анализ эффективности мексидола в комплексном лечении больных с ишемическим инсультом. Журн неврол и психиатр 2010;57-9.</p><p>Румянцева С.А., Евсеев В.Н., Елисеев Е.В. Антиоксидантная терапия при остром ишемическом инсульте. Атмосфера. Нервн бол 2009;8-12.</p><p>Скворцова В.И., Стаховская Л.В., Нарциссов Я.Р. и др. Рандомизированное двойное слепое плацебоконтролируемое исследование эффективности и безопасности мексидола в комплексной терапии ишемического инсульта в остром периоде. Инсульт. Неврол и психиатр 2006;(прил. 18):47-54.</p><p>Parnetti L., Amenta F., Gallai V. Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data. Mech Ageing Dev 2001;122(16):2041-55.</p><p>Barbagallo Sangiorgi G., Barbagallo M, Giordano M. et al. alpha-lycerophosphocholine in the mental recovery of cerebral ischemic attacks. An Italian multicenter clinical trial. Ann N Y Acad Sci 1994;717:253-69.</p><p>Одинак М.М., Вознюк И.А., Пирадов М.А. и др. Многоцентровое (пилотное) исследование эффективности глиатилина при остром ишемическом инсульте. Анн клин и эксперим неврол 2010;1:20-8.</p><p>Tatebayashi Y., Lee M.H., Li L. et al. The dentate gyrus neurogenesis: a therapeutic target for Alzheimer's disease. Acta Neuropathol 2003;105:225-32.</p><p>Ren J.M., Sietsma D., Qiu S. et al. Cerebrolysin enhances functional recovery following focal cerebral infarction in rats. Restor Neurol Neurosci 2007;25:25-31.</p><p>Haffner Z. Cerebrolysin in acute ischemic stroke. Cephalalgia Hung 1999;5:52-3.</p><p>Ladurner G., Kalvach P., Moessler H. et al. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. J Neural Transm 2005;112:415-28.</p><p>Hong Z., Moessler H., Bornstein N. et al. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of Cerebrolysin in patients with acute ischaemic stroke in Asia-CASTA. Int J Stroke 2009;4(5):406-12.</p><p>Ziganshina L.E., Abakumova T., Kuchaeva A. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev 2010(4):CD007026.</p><p>Heiss W.-D. Cerebrolysin in patients with acute ischemic stroke - the CASTA study. 7th World Stroke Congress, Plenary III: Large Clinical Trials Closing Session. Presented October 16, 2010.</p><p>Tazaki Y., Sakai F., E Otomo E. et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke 1988;19(2):211-6.</p><p>Clark W.M., Warach S.J., Pettigrew L.C. et al. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Citicoline Stroke Study Group. Neurology 1997;49(3):671-8.</p><p>Clark W.M., Williams B. J., Selzer K. A. et al. A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke 1999;30(12):2592-7.</p><p>Clark W.M., Wechsler L.R., Sabounjian L.A. et al. A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology 2001;57(9):1595-602.</p><p>Dаvalos A., Castillo J., Alvarez-Sabin J. et al. Oral Citicoline in Acute Ischemic Stroke: An Individual Patient Data Pooling Analysis of Clinical Trials. Stroke 2002;33:2850-7.</p><p>Saver J.L., Wilterdink J. Choline precursors in acute and subacute human stroke: a metaanalysis. Stroke 2002;33:353.</p><p>Bolland K., Whitehead J., Cobo E. et al. Evaluation of a sequential global test of improved recovery following stroke as applied to the ICTUS trial of citicoline. Pharm Stat 2009;8(2):136-49.</p><p>Belayev L., Liu Y., Zhao V. et al. Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke 2001;32:553-60.</p><p>Ginsberg M.D., Palesch Y.Y., Martin R.H. et al. The albumin in acute stroke (ALIAS) multicenter clinical trial: safety analysis of part and rationale and design of part 2. Stroke 2011;42(1):119-27.</p><p>Gutiеrrez M., Merino J.J., de Lecinana M.A. et al. Cerebral protection, brain repair, plasticity and cell therapy in ischemic stroke. Cerebrovasc Dis 2009;27(Suppl. 1):177-86.</p><p>Kondziolka D., Villemagne V.L., Wechsler L. et al. Neurotransplantation for patients with subcortical motor stroke: a phase 2 randomized trial. J Neurosurg, 2005;103:38-45.</p><p>Kondziolka D., Wechsler L., Goldstein S. et al. Transplantation of cultured human neuronal cells for patients with stroke. Neurology 2000;55:565-9.</p><p>Bang O.Y., Lee J.S., Lee P.H. et al. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol 2005;57:874-82.</p><p>Пирадов М.А., Сергеев Д.В., Танашян М.М. Применение клеток пуповинной крови в реабилитации пациентов, перенесших ишемический инсульт. В кн.: Терапевтический потенциал клеток пуповинной крови при негематологических заболеваниях. Под ред. М.А. Пальцева, В.Н. Смирнова. М.: Медицина, 2011;126-33.</p><p>Kammersgaard L.P., Rasmussen B. H., Jorgensen H.S. et al. Feasibility and safety of inducing modest hypothermia in awake patients with acute stroke through surface cooling: A case-control study: the Copenhagen Stroke Study. Stroke 2000;31:2251-6.</p><p>De Georgia M.A., Krieger D. W., AbouChebl A. et al. Cooling for Acute Ischemic Brain Damage (COOL AID): a feasibility trial of endovascular cooling. Neurology 2004;63:312-7.</p><p>Guluma K.Z., Hemmen T.M., Olsen S.E. et al. A trial of therapeutic hypothermia via endovascular approach in awake patients with acute ischemic stroke: methodology. Acad Emerg Med 2006;13:820-7.</p><p>Froehler M.T., Ovbiagele B. Therapeutic hypothermia for acute ischemic stroke. Expert Rev Cardiovasc Ther 2010;8(4):593-603.</p><p>Van der Worp H.B., Macleod M. R., Kollmar R. Therapeutic hypothermia for acute ischemic stroke: ready to start large randomized trials- J Cereb Blood Flow Metab 2010;30(6):1079-93.</p><p>Yenari M.A., Hemmen T.M. Therapeutic hypothermia for brain ischemia: where have we come and where do we go- Stroke 2010;41(Suppl. 10):S72-4.</p><p>Hemmen T.M., Raman R., Guluma K.Z. et al. Intravenous thrombolysis plus hypothermia for acute treatment of ischemic stroke (ICTuSL): final results. Stroke 2010;41(10):2265-70.</p><p>Donnan G.A., Davis S.M. Parsons M.W. et al. How to make better use of thrombolytic therapy in acute ischemic stroke. Nat Rev Neurol 2011;7(7):400-9.</p><p>Chavez J.C., Hurko O., Barone F.C. et al. Pharmacologic interventions for stroke: looking beyond the thrombolysis time window into the penumbra with biomarkers, not a stopwatch. Stroke 2009;40(10):e558-е563.</p><p>Sutherland B.A., Papadakis M., Chen R.-L. et al. Cerebral blood flow alteration in neuroprotection following cerebral ischaemia. J Physiol 2011;589(Pt 17):4105-14.</p><p>Lu M. Assessing combination treatments in acute stroke: preclinical experiences. Behav Brain Res 2005;162(2):165-72.</p><p>Amaro S., Canovas D., Castellanos M. et al. The URICO-ICTUS study, a phase 3 study of combined treatment with uric acid and rtPA administered intravenously in acute ischaemic stroke patients within the first 4.5 h of onset of symptoms. Int J Stroke 2010;5(4):325-8.</p><p>Logallo N., Naess H., Idicula T.T. et al. Serum uric acid: neuroprotection in thrombolysis. The Bergen NORSTROKE study. BMC Neurol 2011;11:114.</p></div><br />

For citation:

Sergeyev D.V., Piradov M.A., Maksimova M.Y., Domashenko M.A., Sergeyeva A.N., Okhtova F.R. New possibilities of neuroprotection in ischemic stroke. Neurology, Neuropsychiatry, Psychosomatics. 2011;3(4):56-63. (In Russ.)

Views: 528

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)